COMMUNIQUÉS West-GlobeNewswire

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
27/07/2026
VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the [...]
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
27/07/2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical- [...]
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
27/07/2026
Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of [...]
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
27/07/2026
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with [...]
InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study
27/07/2026
BEIJING, July 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that its novel TYK2 [...]
Novo Nordisk A/S - share repurchase programme
27/07/2026
Bagsværd, Denmark, 27 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Vireo Growth Inc. to Acquire Planet 13 Holdings Inc.
27/07/2026
Transaction expected to deepen Vireo's positions in Nevada and Florida, complement its growing Illinois platform, and further strengthen one of the industry's broadest multi-state cannabis operating platforms [...]
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
27/07/2026
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients – – Activity compares favorably with [...]
Cato Healthcare Supply Appoints Ryan F. Zackon as President and Chief Executive Officer
27/07/2026
Experienced Supply Chain Leader Strengthens Executive Leadership Team to Accelerate Growth, Innovation, and International Expansion DALLAS, July 27, 2026 (GLOBE NEWSWIRE) -- Cato Healthcare Supply, a leading healthcare [...]
Flourish Health Raises $46M to Scale Intensive Mental Health Care for Youth in Crisis
27/07/2026
Funding fuels national expansion of model that delivers proven outcomes for high-acuity kids through psychiatrist-led Care Pods and an AI-enabled care delivery platform RICHMOND, Va., July 27, 2026 (GLOBE NEWSWIRE) -- [...]
Cristcot Presents Poster and Select Oral Presentation for Implementing Endocrine Principles to Assess Safety and Compliance within a Clinical Trial at ENDO 2026
27/07/2026
-- Study findings create a framework of protocols for implementing endocrine principles to assess compliance within a clinical trial that can be deployed across medical specialties -- -- Building in hypothalamic- [...]
Vivos Inc. (OTCQB: RDGL) Reports Second Quarter 2026 Progress and Corporate Update
27/07/2026
Kennewick, WA, July 27, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ , is pleased to share this update on the meaningful advancements the [...]
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
27/07/2026
The offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral [...]
NewGen to Acquire Additional 3% of K25.ai at US$250 Million Valuation Following Strong Community Beta; Strengthening Market Cap Above US$5 Million
27/07/2026
Follow-on investment would increase NewGen’s aggregate ownership to 13% BANGKOK, July 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified [...]
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
27/07/2026
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced [...]
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
27/07/2026
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artificial intelligence [...]
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
27/07/2026
SKNJCT-005 registrational clinical study protocol strengthened through planned implementation of FDA recommendations, including combined clinical and histological clearance endpoints and extended patient follow-up [...]
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
27/07/2026
Lumara Bio brings together ITM's existing pipeline of early- and late-stage radiopharmaceutical therapies, including lead drug candidate 177 Lu-edotreotide (ITM-11), into a single, dedicated division New drug [...]
Idorsia advances global rollout of QUVIVIQ with Jamjoom Pharma partnership in Saudi Arabia and the Levant
27/07/2026
Exclusive agreement with Jamjoom Pharma covers commercialization and distribution of QUVIVIQ™ (daridorexant) in Saudi Arabia and the Levant region Allschwil, Switzerland – July 27, 2026 Idorsia Ltd (SIX: IDIA) has [...]

Pages